Novo Nordisk’s attempt to create a successor to its weight loss blockbuster Wegovy may have taken a hit with recent ...

Novo Nordisk NVO shares have lost 15.2% so far this month compared with the industry’s decline of 4.6%. The company has also ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Novo Nordisk already has a fairly well-stocked pipeline of candidates, but one of its near-term hopes – CagriSema, which ...

Data on the subcutaneous version of amycretin is due next year, and Novo Nordisk also presented early data on another oral therapy, CBR1 inverse agonist monlunabant (INV-202), which showed a 3% ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Novo Nordisk’s amycretin is a single molecule designed to bind to two targets to spark weight loss — a different approach than some of the pharma giant’s other efforts to develop next ...

Shares of Novo Nordisk (NVO) are sliding in Monday trading ... profile similar to tirzepatide increases the importance of amycretin as a next-gen molecule to sustain the obesity franchise in ...

Novo Nordisk A/S (NVO): Among Renaissance Technologies ... Besides, last month the Amycretin trial results were released and stock showed an upward hike due to the satisfying results.